AACR21: Sanofi rolls out new data for early-stage 'non-alpha' IL-2. Early feedback? Interesting, but mostly meh
When Paul Hudson over at Sanofi inked a $2.5 billion buyout of cancer player Synthorx in late 2019, one of the centerpieces of the deal was an IL-2 the French drugmaker envisioned as the perfect partner to its immunotherapy portfolio. Now, Sanofi is ready to roll out human data for that candidate, and the results have earned a resounding “meh.”
Sanofi’s engineered “non-alpha” IL-2 THOR-707 posted a meager three partial responses across two cohorts as a monotherapy and in combination with Merck’s Keytruda for a range of advanced or metastatic solid tumors, according to Phase I data presented Saturday at the virtual AACR meeting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.